Sonoma Pharmaceuticals (STU:O8Z) Cash per Share : €3.09 (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sonoma Pharmaceuticals Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Sonoma Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2024 was €3.09.

Sonoma Pharmaceuticals Cash per Share Historical Data

The historical data trend for Sonoma Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Cash per Share Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash per Share

Get a 7-Day Free Trial

37.53

33.76

43.33

14.45

3.69

Sonoma Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash per Share	Get a 7-Day Free Trial															3.23	3.69	2.53	2.74	3.09

Sonoma Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Sonoma Pharmaceuticals's Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	2.878	/	0.78
	=	3.69

Sonoma Pharmaceuticals's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	5	/	1.62
	=	3.09

Sonoma Pharmaceuticals (STU:O8Z) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Sonoma Pharmaceuticals Cash per Share Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (STU:O8Z) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

SNOA:USA

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Sonoma Pharmaceuticals Headlines

No Headlines